How to Solve the Production Challenges of AAVs for Gene Therapy
CEVEC Pharmaceuticals has found a solution and developed a platform that can produce adeno-associated viral vectors (AAVs) as easily as if they were monoclonal antibodies.
Labiotech, June 3, 2020
Read the interview with Nicole Faust, CEO of CEVEC